Shark Tank Judge Namita Thapar’s Emcure Pharma Readies To Go Public In Rs. 1,952 Crore IPO

For the last several years, Namita Thapar has been evaluating all manner of businesses on Shark Tank. She’s now set to have her own business evaluated by India’s investors.

The IPO of Emcure Pharmaceuticals, in which Namita Thapar is the Executive Director, opens of 3rd July. Through the public offer, the company plans to raise around Rs. 1,952 crore from investors. The company’s shares’ price band is set at Rs. 960 to Rs. 1,108 per equity share.

Thapar herself holds 6,339,800 Emcure shares, representing a 3.5 percent stake in the company. She will sell 1,268,600 Emcure shares in the offer-for-sale (OFS). At the upper end of the price band, Thapar will make Rs. 126 crore from the IPO.

Emcure Pharmaceuticals was founded by Namita Thapar’s father Satish Mehta in 1981, and he continues to serve as the company’s CEO. Thapar, though, hadn’t joined the family business immediately — she had become a Chartered Accountant, and then gone to Duke University for her MBA. After her MBA, she spent 6 years with medical device company Guidant Corporation in business finance. She then relocated to India, and began working with Emcure Pharmaceuticals, joining as the company’s CFO. She was later appointed an Executive Director of Emcure Pharmaceuticals.

Emcure is headquartered in Pune, and is a leading Indian pharmaceutical company engaged in developing, manufacturing, and globally marketing a broad range of pharmaceutical products across several major therapeutic areas. The company has an established presence in key therapeutic areas such as gynecology, cardiology, blood-related conditions, oncology, respiratory, central nervous system, and HIV. Emcure has a strong global presence, with operations in over 70 countries, including India, Europe, and Canada. It has 5 dedicated R&D centers and 13 manufacturing facilities across India. Around 50 percent of the company’s revenue and profit comes from foreign markets.

Emcure’s IPO comes after a muted few years for India’s pharma stocks. The last few quarters, however, seen a raging bull market in Indian equities, and the election results seem to have spurred the markets even further. As such, even though popular memes from Shark Tank show as her as being “out” on most investments, Namita Thapar will hope that Indian investors will be all in on her newly-public company.